I agree with @Daniel V. Catenacci with regards to the role of systemic therapy after sorafenib in patients with unresectable/non-transplantable/metastatic HCC. I also agree that assessment of performance status, severity of liver disease (Child-Pugh score), and other comorbidities are important...